MindWalk Holdings Corp.

MindWalk Holdings Corp. announced the launch of ReefIQ™, a new biological context layer designed for AI drug discovery and biologics development. ReefIQ™ leverages MindWalk's proprietary HYFT® technology to transform fragmented biological data into a governed, queryable context for AI reasoning workflows. This new layer aims to preserve valuable insights from all discovery programs, enriching future efforts and integrating with the company's existing LensAI™ platform, which is already in use with life-sciences customers.

MindWalk Holdings Corp. reported preclinical dengue data that supports a computational prediction generated by its HYFT® platform. The platform identified a candidate pan-serotype structural target on the dengue virus, and subsequent animal immunization with immunogens designed on this target generated antibodies that cross-reacted with antigens of all four dengue serotypes. This clear and consistent trend was reproduced across two independent campaigns, providing MindWalk's first public evidence that its AI-driven platform can connect computational predictions to measurable biological outcomes. Future studies will assess the antibodies' functional profile, including neutralization and interaction with ADE pathways.

MindWalk Holdings Corp. announced the launch of its Pandemic Response Platform, utilizing its proprietary HYFT® biological pattern system and LensAI™ platform. This platform is designed for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against rapidly mutating RNA viruses. It targets the structural constraints viruses must preserve, bypassing the limitations of surface-focused countermeasures. The platform is currently deployed on the company's pan-serotype Dengue and universal Influenza programs.